Real-world ALK Testing Trends in Patients with Advanced Non-small Cell Lung Cancer in the United States
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world ALK Testing Trends in Patients with Advanced Non-small Cell Lung Cancer in the United States
Authors
Keywords
-
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-10-14
DOI
10.1016/j.cllc.2022.09.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data
- (2021) Ani John et al. ADVANCES IN THERAPY
- Evaluating eligibility criteria of oncology trials using real-world data and AI
- (2021) Ruishan Liu et al. NATURE
- Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non‐Small Cell Lung Cancer in U.S. Community Medical Centers
- (2021) Eric H. Bernicker et al. ONCOLOGIST
- Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists
- (2021) David M. Waterhouse et al. Clinical Lung Cancer
- Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer
- (2020) Daniel Sheinson et al. LUNG CANCER
- Immunotherapy Treatment Patterns and Outcomes Among ALK+ Patients with Non-small Cell Lung Cancer
- (2020) Mohammad Jahanzeb et al. Clinical Lung Cancer
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer
- (2018) Jessica J. Lin et al. Journal of Thoracic Oncology
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world concordance of clinical practice with ASCO and NCCN guidelines for EGFR/ALK testing in aNSCLC.
- (2017) John E. Ruggiero et al. JOURNAL OF CLINICAL ONCOLOGY
- High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods
- (2017) Dan Su et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
- (2017) Lee Pai‐Scherf et al. ONCOLOGIST
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†
- (2015) C. Lim et al. ANNALS OF ONCOLOGY
- ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
- (2015) Annie Guérin et al. Cancer Epidemiology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis
- (2014) Liang Fan et al. PLoS One
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started